Étiquette : effets indésirables

Smoking weed and coronavirus : Even occasional use raises risk of Covid-19 complications, Sandee LaMotte, CNN, avril 2020

Smoking weed and coronavirus : Even occasional use raises risk of Covid-19 complications By Sandee LaMotte, CNN Updated 1222 GMT (2022 HKT) April 10, 2020 (CNN)If you're smoking weed to ease your stress during the coronavirus pandemic, experts say it's time to think twice. Smoking marijuana, even occasionally, can increase your risk for more severe complications from Covid-19, the disease caused by the novel coronavirus. Coronavirus symptoms: 10 key indicators and what to do "What happens to your airways when you smoke cannabis is that it causes some degree of inflammation, very similar to bronchitis, very similar to the type of inflammation that cigarette [...]

Lire la suite

LE CBD EST-IL PSYCHOACTIF ? François-Olivier GAGNON-HÉBERT, 2019

LE CBD EST-IL PSYCHOACTIF ? François-Olivier GAGNON-HÉBERT – Chercheur Postdoctoral/ Université de Moncton, Canada La Lettre du RESPADD, 2019, 36, 4-5 https://www.respadd.org/lettre-n36-octobre-2019/   Il semble y avoir une véritable résurgence du cannabis dans les débats publics à l’échelle internationale depuis quelques années. Cette plante cultivée depuis les premiers balbutiements des sociétés humaines néolithiques grégaires (Warf 2014) ne laisse personne indifférent. Bien que les apologistes et les détracteurs de l’usage de la plante ne s’entendent généralement sur aucun point, tous s’entendent sur la réalité suivante : il s’agit d’une question fort complexe et épineuse. Au-delà des débats moraux et sociétaux, il n’en demeure pas moins que le cannabis [...]

Lire la suite

The Psychiatric Consequences of Cannabinoids, Joao P. De Aquino et al., 2018

The Psychiatric Consequences of Cannabinoids Joao P. De Aquino, Mohamed Sherif, Rajiv Radhakrishnan, John D. Cahill, Mohini Ranganathan and Deepak C. D’Souza Clinical Therapeutics, 2018, 40, (9), 14481456 Doi : 10.1016/j.clinthera.2018.03.013   ABSTRACT With rising rates of cannabis use in the general population and an increasing number of US states legalizing both recreational and medical cannabis use, it is important to be informed about the adverse consequences of cannabinoids. This Commentary provides an overview of the psychiatric effects of plant-based and synthetic cannabinoids, differentiating acute effects from effects associated with persistent use. Cannabinoids produce multiphasic and dose dependent effects on anxiety, mood, and perception, in addition [...]

Lire la suite

Medical Marijuana Use in Oncology : A Review, Gianna Wilkie et al., 2016

Medical Marijuana Use in Oncology : A Review Gianna Wilkie,  Bachir Sakr, Tina Rizack JAMA Oncology, 2016, 2, (5), 670-675. doi:10.1001/jamaoncol.2016.0155   IMPORTANCE : Medicinal marijuana use is currently legal in 23 states and the District of Columbia. As more states approve marijuana use for medical indications, physicians will be asked by their patients for more information regarding the risks and benefits of use. This article reviews the history, adverse effects, and proposed mechanisms of action of marijuana and summarizes the available literature regarding symptom relief and therapeutic value in patients with cancer. OBSERVATIONS : Marijuana in oncologymay have potential for use as an antiemetic, for [...]

Lire la suite

LSD before Leary – Sidney Cohen’ s Critique of 1950s Psychedelic Drug Research, Steven J. Novak, 1997

LSD before Leary - Sidney Cohen' s Critique of 1950s Psychedelic Drug Research Steven J. Novak Isis, 1997, Vol. 88, No. 1, pp. 87-110. http://links.jstor.org/sici?sici=0021-1753%28199703%2988%3A1%3C87%3ALBLSCC%3E2.0.CO%3B2-W   ABSTRACT In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychoto-mimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were [...]

Lire la suite

Neurotoxicity and LSD treatment: a follow-up study of 151 patients in Denmark, Jens Knud Larsen, 2016

Neurotoxicity and LSD treatment : a follow-up study of 151 patients in Denmark Jens Knud Larsen University Hospital of Aarhus, Risskov, Denmark History of Psychiatry, 2016, Vol. 27, (2), 172–189 DOI: 10.1177/0957154X16629902   Abstract LSD was introduced in psychiatry in the 1950s. Between 1960 and 1973, nearly 400 patients were treated with LSD in Denmark. By 1964, one homicide, two suicides and four suicide attempts had been reported. In 1986 the Danish LSD Damages Law was passed after complaints by only one patient. According to the Law, all 154 applicants received financial compensation for LSD-inflicted harm. The Danish State Archives has preserved the case material of 151 [...]

Lire la suite

The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series, Joseph El-Khoury & Nayiri Sahakian, 2015

The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series Joseph El-Khoury & Nayiri Sahakian Journal of Psychoactive Drugs, 2015, 47, 4, 286-292 https://doi.org/10.1080/02791072.2015.1073815   Abstract The association of substance abuse and psychotic disorders is of interest to clinicians, academics, and lawmakers. Commonly abused substances, such as cannabis, cocaine, amphetamines, and alcohol, have all been associated with substance-induced psychosis. Hallucinogens can induce desired psychedelic effects and undesirable psychomimetic reactions. These are usually transient and resolve once the duration of action is over. Sometimes, these effects persist, causing distress and requiring intervention. This article focuses on the hallucinogenic substance Salvia divinorum, [...]

Lire la suite

Motives and Side-Effects of Microdosing With Psychedelics Among Users, Nadia R. P. W. Hutten et al., 2019

Motives and Side-Effects of Microdosing With Psychedelics Among Users Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers International Journal of Neuropsychopharmacology, 2019, 1–9 doi:10.1093/ijnp/pyz029   Abstract Background : Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects. Methods : An [...]

Lire la suite

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act, Matthew W. Johnson et al., 2018

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfiel Neuropharmacology, 2018, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012 a b s t r a c t This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to [...]

Lire la suite

Associations between Adolescent Cannabis Use and Neuropsychological Decline : A Longitudinal Co-Twin Control Study, Madeline H. Meier et al., 2018

Associations between Adolescent Cannabis Use and Neuropsychological Decline : A Longitudinal Co-Twin Control Study Madeline H. Meier, Avshalom Caspi, Andrea Danese, Helen L. Fisher, Renate Houts, Louise Arseneault, & Terrie E. Moffitt Addiction. 2018, 113, (2), 257-265. doi: 10.1111/add.13946.   Abstract Aims : This study tested whether adolescents who used cannabis or met criteria for cannabis dependence showed neuropsychological impairment prior to cannabis initiation and neuropsychological decline from before to after cannabis initiation. Design : A longitudinal co-twin control study. Setting and Participants : Participants were 1,989 twins from the Environmental Risk (E-Risk) Longitudinal Twin Study, a nationally representative birth cohort of twins born in England and Wales [...]

Lire la suite